Characteristics of the study subjects
| . | Controls . | ET . | JAK2V617F . | PV . | JAK2V617F . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative . | Heterozygous . | P . | Negative . | Heterozygous . | Homozygous . | P . | ||||
| n | 60 | 59 | 29 | 30 | 30 | 3 | 17 | 10 | ||
| Male/female | 18/42 | 18/41 | 10/19 | 8/22 | 19/11 | 2/1 | 12/5 | 5/5 | ||
| Age, y (range) | 57 (27-75) | 59 (23-82) | 56 (30-78) | 65 (28-82) | 59 (19-80) | 52 (18-77) | 59 (35-80) | 67 (51-78) | ||
| Platelets, ×109/L (range) | 258 (149-428) | 679* (319-1744) | 722* (335-1601) | 638* (319-1744) | NS | 510* (164-1085) | 571 (400-670) | 557* (261-1085) | 418* (164-954) | NS |
| White blood cells, ×109/L (range) | 6.84 (4.32-10.3) | 7.6* (3.40-17.8) | 7.31 (3.4-11.6) | 7.99* (4.6-17.8) | NS | 10.24* (3.45-36.21) | 7.76 (6.3-10.4) | 9.33* (3.61-23.82) | 12.4* (3.45-36.21) | NS |
| Neutrophils, ×109/L (range) | 3.94 (3.85-6.68) | 4.7* (1.7-12.46) | 4.42 (1.7-8.3) | 5.07* (2.5-12.46) | NS | 7.17* (1.78-30.8) | 4.72 (3.59-6.42) | 6.30* (1.78-15.48) | 9.5* (2.5-30.8) | NS |
| Red blood cells, ×109/L (range) | 4.96 (4.17-5.66) | 4.54* (3.04-5.88) | 4.7 (3.04-5.88) | 4.38* (3.18-5.75) | NS | 5.72* (3.85-7.24) | 6.15 (5.1-7.2) | 5.62* (4.03-7.24) | 5.67* (3.85-6.68) | NS |
| History of thrombosis | — | 15 (25%) | 7 (24%) | 8 (27%) | 12 (40%) | — | 4 (23%) | 8 (80%) | ||
| . | Controls . | ET . | JAK2V617F . | PV . | JAK2V617F . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Negative . | Heterozygous . | P . | Negative . | Heterozygous . | Homozygous . | P . | ||||
| n | 60 | 59 | 29 | 30 | 30 | 3 | 17 | 10 | ||
| Male/female | 18/42 | 18/41 | 10/19 | 8/22 | 19/11 | 2/1 | 12/5 | 5/5 | ||
| Age, y (range) | 57 (27-75) | 59 (23-82) | 56 (30-78) | 65 (28-82) | 59 (19-80) | 52 (18-77) | 59 (35-80) | 67 (51-78) | ||
| Platelets, ×109/L (range) | 258 (149-428) | 679* (319-1744) | 722* (335-1601) | 638* (319-1744) | NS | 510* (164-1085) | 571 (400-670) | 557* (261-1085) | 418* (164-954) | NS |
| White blood cells, ×109/L (range) | 6.84 (4.32-10.3) | 7.6* (3.40-17.8) | 7.31 (3.4-11.6) | 7.99* (4.6-17.8) | NS | 10.24* (3.45-36.21) | 7.76 (6.3-10.4) | 9.33* (3.61-23.82) | 12.4* (3.45-36.21) | NS |
| Neutrophils, ×109/L (range) | 3.94 (3.85-6.68) | 4.7* (1.7-12.46) | 4.42 (1.7-8.3) | 5.07* (2.5-12.46) | NS | 7.17* (1.78-30.8) | 4.72 (3.59-6.42) | 6.30* (1.78-15.48) | 9.5* (2.5-30.8) | NS |
| Red blood cells, ×109/L (range) | 4.96 (4.17-5.66) | 4.54* (3.04-5.88) | 4.7 (3.04-5.88) | 4.38* (3.18-5.75) | NS | 5.72* (3.85-7.24) | 6.15 (5.1-7.2) | 5.62* (4.03-7.24) | 5.67* (3.85-6.68) | NS |
| History of thrombosis | — | 15 (25%) | 7 (24%) | 8 (27%) | 12 (40%) | — | 4 (23%) | 8 (80%) | ||
The data are tabulated according to disease type (ET or PV) and to JAK2V617F mutational status. Data presented as number for sex and history of thrombosis, mean (range) for the other parameters.
NS indicates not significant.
P < .05 versus controls.